Atovaquone en es it fr

Atovaquone Brand names, Atovaquone Analogs

Atovaquone Brand Names Mixture

  • No information avaliable

Atovaquone Chemical_Formula


Atovaquone RX_link

Atovaquone fda sheet

Atovaquone FDA

Atovaquone msds (material safety sheet)

Atovaquone Synthesis Reference

No information avaliable

Atovaquone Molecular Weight

366.837 g/mol

Atovaquone Melting Point

No information avaliable

Atovaquone H2O Solubility

Practically insoluble

Atovaquone State


Atovaquone LogP


Atovaquone Dosage Forms

Suspension; Tablet

Atovaquone Indication

For the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.

Atovaquone Pharmacology

Atovaquone is a highly lipophilic drug that closely resembles the structure ubiquinone. Its inhibitory effect being comparable to ubiquinone, in sensitive parasites atovaquone can act by selectively affecting mitochondrial electron transport and parallel processes such as ATP and pyrimidine biosynthesis. For illustration, cytochrome bc1 complex (complex III) seems to serve as a highly discriminating molecular target for atovaquone in Plasmodia

Atovaquone Absorption

The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.

Atovaquone side effects and Toxicity

The median lethal dose is higher than the maximum oral dose tested in mice and rats (1825 mg/kg per day). Overdoses up to 31,500 mg of atovaquone have been reported. In one such patient who also took an unspecified dose of dapsone, methemoglobinemia occurred. Rash has also been reported after overdose.

Atovaquone Patient Information

Atovaquone Organisms Affected

Plasmodium and other